EFFECTS OF LOVASTATIN ON A HUMAN MYELOMA CELL-LINE - INCREASED SENSITIVITY OF A MULTIDRUG-RESISTANT SUBLINE THAT EXPRESSES THE 170-KDA P-GLYCOPROTEIN

被引:32
作者
HOLMBERG, M
SANDBERG, C
NYGREN, P
LARSSON, R
机构
[1] UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT CLIN PHARMACOL,S-75185 UPPSALA,SWEDEN
关键词
FMCA; LOVASTATIN; MDR; P-GLYCOPROTEIN;
D O I
10.1097/00001813-199410000-00012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using a fluorometric microculture cytotoxicity assay for measuring cell viability and proliferation we examine the cytotoxic effect of lovastatin on a drug sensitive myeloma cell line (RPMI 8226) and a multidrug resistant (MDR) clone (8226/Dox40), that was approximately 100-fold less sensitive to doxorubicin. The RPMI 8226 cells were sensitive to lovastatin with an IC50 of 15.8 mu g/ml. However, the MDR subline exhibited a collateral sensitivity to lovastatin, with an IC50 of 1.7 mu M, thus having a 9.3-fold greater sensitivity to lovastatin than the parental cell line. The combination of doxorubicin and lovastatin did not show any synergistic or antagonistic effects on any of the cell lines. The increased sensitivity to lovastatin of the P-gp 170-expressing MDR cells 8226/Dox40 might be part of a more general phenomenon that merits further investigation.
引用
收藏
页码:598 / 600
页数:3
相关论文
共 13 条
[1]   CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY [J].
BUCHWALD, H .
LANCET, 1992, 339 (8802) :1154-1156
[2]  
Chen H W, 1978, Prog Exp Tumor Res, V22, P275
[3]  
DALTON WS, 1986, CANCER RES, V46, P5125
[4]   EFFECTS OF MEVINOLIN AND MEVALONATE ON CELL-GROWTH IN SEVERAL TRANSFORMED-CELL LINES [J].
FAIRBANKS, KP ;
BARBU, VD ;
WITTE, LD ;
WEINSTEIN, IB ;
GOODMAN, DS .
JOURNAL OF CELLULAR PHYSIOLOGY, 1986, 127 (02) :216-222
[5]  
HINDENBURG AA, 1989, CANCER RES, V49, P4607
[6]  
KEIZER HG, 1989, CANCER RES, V49, P2988
[7]  
LARSSON R, 1989, ANTICANCER RES, V9, P1111
[8]  
Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J
[9]  
MORRIS PJ, 1992, EFFECT LOVASTATIN AD
[10]  
MORRIS T J, 1991, Surgical Forum (Chicago), V42, P452